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ABSTRACT 
Objective: To develop and validate a sensitive liquid chromatography-electrospray ionization-tandem mass spectrometric (LC-ESI-MS/MS) 
technique for the quantification of dapagliflozin and saxagliptin in plasma by linagliptin as internal standard.  
Methods: Chromatography was achieved on hypersil C18 (50 mmx4 mm) 5 µ analytical column with 0.1% formic acid and acetonitrile (25:75 V/V) 
as mobile phase at 0.7 ml/min flow rate. Dapagliflozin, saxagliptin, and linagliptin were detected at m/z 409.14/135.0, m/z 316.2/180.13 and m/z 
472.54/456.21 respectively. Drugs and internal standard were extracted by LLE (liquid-liquid extraction). 
Results: Developed technique was validated over 0.5-1500.0 ng/ml linear concentration range for dapagliflozin and 2.00-2000.0 ng/ml for 
saxagliptin. This method established with intra-batch and inter-batch precision within 2.44-8.12% and 1.25-7.14 % for dapagliflozin and 1.84-7.5 % 
and 1.02–6.00 % for saxagliptin. This method established with intra-batch and inter-batch accuracy for dapagliflozin within 98.86-103% and 96.98-
102 % respectively and for saxagliptin within 98.05-109.06 % and 97.00-104.00 % respectively. 
Conclusion: Both dapagliflozin and saxagliptin were stable during three freeze-thaw cycles, long term and bench-top stability studies. The 
developed method was useful for the routine analysis of dapagliflozin and saxagliptin simultaneously in plasma samples. 
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Dapagliflozin (DPG) is useful in controlling diabetes mellitus type-2 
and improves glycemic control when mixed with diet and exercise. 
IUPAC name of the drug is (2S, 3R, 4R, 5S, 6R)–2-[4-Chloro-3-(4-
ethoxybenzyl) phenyl]-6-(hydroxymethyl) tetrahydro-2H-pyran-
3,4,5-triol [1]. Drug inhibits Na+/glucose co-transporter-2, which 
inhibits the kidney glucose reabsorption. Using dapagliflozin leads to 
heavy glycosuria (glucose excretion in the urine), which can lead to 
weight loss and tiredness [2].  
Chemically Saxagliptin (SXG) designated as (1S, 3S, 5S)-2-[(2S)-2-
amino-2-(3-hydroxy-1-adamantyl) acetyl]-2-azabicyclo [3.1.0] 
hexane-3-carbonitrile. It belongs to the diabetes medications class 
called dipeptidyl peptidase-4 (DPP-4) blockers. DPP-4 
damages incretin hormones which belongs to an enzyme [3]. 
Saxagliptin reduces the metobolism of incretin hormones (as DPP-4 
inhibitor) and in human body, the concentration of these hormones 
will increases. This increase in hormones is responsible for the 
beneficial activities of saxagliptin and increases insulin creation with 
response to diet and reduces the gluconeogenesis in liver. DPP-4's 
action in the regulation of blood glucose is thought to be through the 
breakdown of GIP and GLP-1. Because these hormones are active in 
response to high blood glucose levels (and are less reactive in 
response to low blood glucose), the risk of dangerously 
hypoglycemia is very less with saxagliptin monotherapy [4, 5]. 
 
 
Fig. 1: Structure of dapagliflozin 
 
Fig. 1: Structure of saxagliptin 
 
Literature survey of these drugs revealed several analytical 
techniques for the determination of these drugs in formulations 
which includes the methods such as UV-spectroscopy [6, 7], high-
performance liquid chromatography (HPLC) [8-11] and LC-MS/MS 
[13]. Present research work aimed to develop specific and accurate 
LC-MS/MS method with low retention time. 
MATERIALS AND METHODS 
Reagents and chemicals  
DPG, SXG and linagliptin (Internal Standard) of reference grade were 
provided by MSN Labs, Hyderabad as gift samples. Hypersil C18 (50 
mmx4 mm) 5 µ analytical columns were procured from Thermo 
Fischer Pvt. Ltd. Acetonitrile and methanol of HPLC-grade were 
procured from S. D-Fine Chemicals. Water used in present work was 
purified by means of Milli-Q water purification systems from 
Millipore. Analytical grade formic acid was bought from E. Merck 
Mumbai, India.  
Instrumentation 
The LC-ESI-MS/MS system comprised a Liquid Chromatography 
(Shimadzu LC10) from Shimadzu combined to an MS/MS (API-3000) 
from Applied Biosystems Sciex, Canada, furnished with a Turbo-Ion 
Spray source for ion production. Monitoring of data and integration 
of chromatograms were processed by Analyst Software of Applied 
Biosystems, version-1.4.1. 
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The components were eluted by infusing the sample solution into 
hypersil C18 (50 mmx4 mm) 5 µm analytical column at 45 °C using a 
mobile phase composition of 0.1% formic acid and acetonitrile (25:75 
v/v). Mobile phase degasification was performed by filtration (0.5 µ filter 
paper) and sonication of the mobile phase. Analytes were separated with 
isocratic elution with a flow of mobile phase at 0.7 ml/min through 
analytical column. The autosampler temperature was adjusted to 5 °C. 
Mass scanning optimization 
DPG and SXG stock solutions were prepared by dissolving the 
components in HPLC-grade methanol. Further dilutions were made 
with the solvent mixture of methanol and water in the composition 
of 50:50 v/v. The analytes were analysed by MRM (multiple reaction 
monitoring) of the transition pairs of transitions m/z 409.14/135.0, 
m/z 316.2/180.13 and m/z 472.54/456.21 for DPG, SXG and 
internal standard (IS) respectively. 
Mass spectrometry 
The electro-spray interface heater (IHE) was switch to on mode and Ion 
spray (IS) Voltage was fixed at 4500 V for ionization. The curtain gas 
(nitrogen) was tuned to constant fig. of 12 units and the temperature of 
source (at set point) was 500 °C. The mass instrument parameters were 
adjusted to achieve high sensitivity at unit resolution. The MRM mode for 
DPG, SXG and IS were detected at m/z 409.14/135.0, m/z 316.2/180.13 
and m/z 472.54/456.21 respectively. 
Preparation of quality control and calibration standards 
DPG and SXG stock solution of were prepared in 70% methanol at a 
concentration of 1000 µg/ml. Calibration standards for DPG were 0.5, 1, 
20, 40, 200, 400, 800, 1200 and 1500 ng/ml and for SXG were 2, 4, 20, 
100, 300, 600, 1200, 1500 and 2000 ng/ml. These solutions were 
prepared from stock solution by serial dilution method with 70% 
methanol. High, medium and low concentration quality control (QC) 
standards for DPG (1200, 800 and 1 ng/ml) and for SXG (1500, 900 and 
4 ng/ml) were prepared in the similar way. The stock solution of 
linagliptin IS (1000 µg/ml) was also prepared in 70% methanol and 
further, it was diluted to 5.0 ng/ml concentration. All solutions were 
retained in a freezer at 2-8 °C until actual sample analysis. 
Sample preparation 
To prepare sample solution 0.30 ml of plasma was transferred in to a 
10 ml tube and 50 µl of IS (50.0 ng/ml) was added. The resulting 
solution vortexed for 30 s and further 5 ml of ethyl acetate and butyl 
methyl ether solvent was mixed and vortexed for 10 min in a 
centrifuge at 3000 rpm. Resulting solution was evaporated by the 
application of steam of nitrogen and water bath. Reconstitute with 
250 µl of mobile phase mixture and shake for 2 min. Finally, the 
resulting solution was transferred into an auto-sampler vial and 
infused into a liquid chromatographic system. 
Validation of analytical method 
Method validation was executed according to Food and Drug 
Administration guidelines on Bioanalytical Method Validation [14-18]. 
Selectivity and specificity 
Potential nosiness between analyte and endogenous matrix 
constituents was examined by the analysis of 6 lots blank plasma 
from different source. From each lot, a double blank and a LLOQ 
sample were prepared, infused and analysed [16, 19]. To determine 
potential nosiness between IS and analytes, blank sample spiked 
with analytes separately (at the upper limit of quantification) and IS 
were infused and estimated. Peak areas of components co-eluting 
with analytes should be<20% of LLOQ sample peak area. Peak areas 
of co-eluents of IS, should be<5% of the average IS peak area. The 
measured concentrations of the LLOQ standard samples should 
be<20% from the nominal concentrations. 
Precision and accuracy 
The precision and accuracy of the assay method were assessed by 
analysing 5 duplicates of quality control samples of DPG and SXG at the 
concentration level of LLOQ, LQC, MQC and HQC standards in 3 
analytical runs. Inter-assay accuracy was determined as the relative 
difference between the average measured concentration after 3 runs 
and the nominal concentration [17, 20]. Accuracy should be±20% for 
the LLOQ and±15% for the remaining concentrations. Inter and Intra-
assay precisions were denoted by coefficient of variation (%CV), which 
should be<20% for the LLOQ and<15% for the remaining standards.  
Linearity 
For the estimation of linearity, calibration curves of nine points 
(non-zero standards) were used. Nine non-zero points of 0.5, 1, 20, 
40, 200, 400, 800, 1200 and 1500 ng/ml for DPG and 2, 4, 20, 100, 
300, 600, 1200, 1500 and 2000 ng/ml for SXG were analysed. The 
information from three accuracy and precision lots was considered 
to analyse goodness of fit using 1/x and 1/x2 weighing factor. 
Deviation from nominal concentration should be within±20% for 
LLOQ and within±15% for remaining concentrations. Linear 
coefficient of correlation (r2) should be ≥ 0.98. 
Matrix factor 
Matrix Factor (MF) of analytes in plasma were processed at HQC and 
LQC levels after extraction in six different blank matrix batches. 
Simultaneously six duplicates of equivalent neat quality control 
samples were prepared and estimated [18-22]. Assess the MF for 
analytes and IS in each batch by the application of formula:  
Matrix Factor = (Peak area in the presence of matrix components/ 
Average peak area in aqueous samples). 
Recovery 
Recoveries were determined by matching the mean peak area of 6 
extracted LQC, MQC and HQC samples (1.0, 800.0 and 1200.0 ng/ml 
for DGP and 4.0, 900.0 and 1500.0 ng/ml for SXG) to average peak 
area of 6 spiked samples with the same quantities of high, medium 
and low DGP/SXG quality control samples.  
Dilution integrity 
The concentration of the drug above upper limit of quantification 
(ULOQ) was prepared and precision and accuracy parameters were 
determined. The percentage of nominal concentration should be±15%.  
Autosampler stability 
To estimate autosampler stability, 6 sets of quality control standards 
(LQC and HQC) were prepared and kept in an autosampler. These 
standard samples were infused after 24 h and were estimated 
against freshly spiked calibration standards. The findings when 
compared with nominal concentrations, should be within±15 %. 
Stability  
LQC and HQC samples (n = 6) were regained from the freezer after 3 
freeze and thaw cycles. Samples were stored at-30 °C in 3 cycles of 
24, 48, 72 h. For the long term stability of DPG and SXG in QC 
samples were also estimated by analysis after 4 mo of storage at-25 
°C and-70 °C. Bench-top stability was assessed for 7 h period with 
standard concentrations [23-25]. Stability solutions were prepared 
and extracted along with freshly spiked calibration standards. The 
accuracy and precision of the stability solutions should be±15% of 
their nominal concentrations.  
RESULTS AND DISCUSSION 
Method development and validation 
A sample extraction procedure was employed in the extraction of 
drugs and internal standard from plasma samples. Chromatographic 
conditions were improved through several trials to attain best 
resolution and increase signal to noise ratio of analytes and IS. The 
Mass instrument conditions were optimized by infusing the solution 
directly into electrospray ionization source of the mass system. 
After MRM transitions were adjusted, the organic portion of mobile 
phase was increased to gain a selective and rapid LC technique. A 
good resolution and elution were attained using an isocratic mobile 
phase composition of 0.1% formic acid and acetonitrile (25:75 v/v), 
at 0.7 ml/min flow rate. 
Phanindra et al. 




Six different batches of blank plasma were selected and interference 
of endogenous substances at retention time of analytes and internal 
standard were analysed. Interference of matrix components were 
not observered at the RT and m/z of DPG and SXG and internal 
standard in all the batches screened fig. 3, elucidates the 
representative chromatogram for blank and LLOQ. 
 
 
Fig. 3: Typical chromatograms of DPG, SXG and IS in A) Blank plasma, B) Blank plasma spiked with IS and C) Spiked with LLOQ level 
 
Precision and accuracy 
Precision and accuracy of the method was estimated by 
calculating the intra-day and inter-day batch deviations of three 
quality control samples in 6 replicates: 1.0, 800.0 and 1200.0 
ng/ml for DPG and 4.0, 900.0 and 1500.0 ng/ml for SXG as 
represented in table 1. 
Intra-day precision and accuracy for DPG ranged from 2.44-8.12% 
and 98.86-103% respectively and for SXG ranged from 1.84-7.5 % 
and 98.05-109.06 % respectively. Inter-day precision and accuracy 
fluctuated between 1.25-7.14 % and 96.98-102 % respectively for 
DPG and 1.02–6.00 % and 97.00-104.00 % respectively for SXG. 
These results indicates that the method was accurate, reliable and 
reproducible as all the parameters were within the limit of<15% 
and±15% for precision and accuracy respectively for LQC, MQC 
and HQC and<20% for LLOQ. 
Linearity 
Linearity curve was established in concentration range of 0.5-
1500.0 ng/ml for DPG and 2.0-2000.0 ng/ml for SXG respectively 
in human plasma with a correlation coefficient of [r2] ≥0.99. The 
mean slope and intercept of regression equations were 0.006521 
and 0.002564 for DPG and 0.01652 and-0.03215 for SXG. 
Linearity was found to be acceptable and reproducible. The 
estimated correlation coefficients for DPG and SXG were greater 
than 0.9970 and 0.9960 respectively for all the calibration 
curves (table 2). 
Matrix factor  
The calculated %Coefficient of variance values for HQC and LQC 
samples were 0.35% and 1.89% respectively. The findings were 
within the acceptable limit. The results were shown in the table 3. 
 

















1.0 1.08 8.12 102.84 0.94 7.14 98.12 
800.0 795.95 3.98 98.861 789.32 6.32 96.98 
1200.0 1209.71 2.44 101.94 1206.64 1.25 101.18 
Saxagliptin 
4.0 4.09 7.44 109.06 4.06 5.56 103.11 
900.0 892.05 1.84 98.05 896.81 3.41 98.15 
1500.0 1507.60 1.87 102.51 1509.33 1.02 102.21 
a =6 replicates  
 
Phanindra et al. 




Table 2: Spiked plasma concentration and RSD (%) for DPG and SXG 
Plasma concentration (ng/ml) Concentration measured (mean) (ng/ml)±SD(n) % RSD % Accuracy  
Dapagliflozin 
0.5 0.48±0.159 3.71 96.22 
1.0 1.96±0.266 2.77 97.10 
20.0 20.51±0.912 4.80 103.45 
40.0 40.41±2.501 2.37 101.41 
200.0 211.52±7.234 2.23 109.75 
400.0 408.42±9.367 1.53 102.21 
800.0 814.23±7.208 0.74 105.45 
1200.0 1220.51±0.562 1.52 101.85 
1500.0 1540.41±2.501 0.85 104.37 
Saxagliptin 
2.0 2.13±0.056 2.45 102.43 
4.0 3.98±0.091 3.12 99.14 
20.0 20.85±0.194 4.94 104.52 
100.0 104.97±0.842 4.41 104.97 
300.0 304.21±1.021 1.54 102.38 
600.0 610.04±1.335 1.11 102.03 
1200.0 1189.81±0.914 0.47 94.90 
1500.0 1482.97±0.842 3.52 94.96 
2000.0 1978.21±1.021 2.14 93.31 
n=6 replicates; SD = Standard deviation; RSD=Relative standard deviation 
 
Table 3: Matrix effect data for DPG and SXG 
  Dapagliflozin Saxagliptin 
ID LQC HQC LQC HQC 
Actual concentration (ng/ml) 1 1200 4 1500 
1 0.99 1189 3.89 1479 
2 0.95 1195 3.95 1489 
3 0.95 1206 3.86 1472 
4 1.09 1210 4.5 1510 
5 1.02 1195 4.06 1508 
6 0.96 1208 3.95 1492 
Mean 0.99 1200.5 4.035 1491.67 
±SD 0.05 7.85 0.28 13.89 
% CV 5.02 0.65 5.38 0.93 
% Accuracy 96.75 99.66 100.05 99.4 
SD = Standard deviation; CV= Coefficient of variation 
 
Recovery 
The percentage recovery was estimated by evaluating the absolute peak 
area of DPG, SXG and IS from a plasma sample prepared according to the 
method of analysis. The extent of retrieval of drug analyte and of the 
internal reference standard should be consistent, precise and 
reproducible. The mean overall recovery of DPG and IS was found to be 
96.27% and 96.13% respectively. The mean overall recovery of SXG and 
IS was found to be 89.52% and 94.42% respectively. 
Dilution integrity 
DPG and SXG were diluted up to 20 fold by blank plasma and 
were analyzed with spiked samples above the upper limit of the 
calibration standard and samples with the highest concentration. 
The %nominal was within±15 and the observed precision was 
within<15 %. This demonstrates that the sample can be diluted 
up to 20 times and yet the results are predictable and 
reproducible. 
 
Table 4: Stability data for DPG and SXG 
Drug Concentration 
 (ng/ml) 






%CV mean±SD  
(ng/ml) 
% CV mean±SD  
(ng/ml) 
% CV mean±SD  
(ng/ml) 
% CV 
DPG 1  1±0.14 8.3 1±0.16 4.5 1±0.09 3.45 1±0.2 8.2 
1200 1200±8.12 7.2 1200±7.20 7.5 1200±9.01 5.21 1200±9.0 4.4 
SXG 4 4±0.75 9.1 4±0.95 8.2 4±0.25 5.9 4±0.31 6.3 
1500 1500±7.58 6.4 1500±7.20 6.1 1500±9.01 4.6 1500±9.0 5.4 
SD = Standard deviation; CV= Coefficient of variation. 
 
Stability studies 
The stability data of DPG and SXG, which includes autosampler, long-
term, freeze thaw and bench-top were within the acceptance limit. 
Results were revealed in table 4. 
CONCLUSION 
In this research article an LC-ESI-MS/MS technique for the 
quantification of DPG and SXG in plasma was effectively developed 
and validated. All the validation parameters: selectivity, accuracy, 
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precision, recovery, stability, matrix effect, and dilution integrity 
were within the acceptance limit. The samples for LC-ESI-MS/MS 
analysis were processed by liquid-liquid extraction technique. The 
validated method is also highly sensitive, reliable over the other 
techniques like GC and HPLC. The pharmaceutical formulations 
containing these combinations were successfully estimated by this 
method routinely in human plasma. 
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